Erratum: Corrigendum to “Design of the NIDA clinical trials network validation study of tobacco, alcohol, prescription medications, and substance use/misuse (TAPS) tool” (Contemporary Clinical Trials (2016) 50 (90–97)(S1551714416301331)(10.1016/j.cct.2016.07.013))

Li Tzy Wu, Jennifer McNeely, Geetha A. Subramaniam, Gaurav Sharma, Paul VanVeldhuisen, Robert P. Schwartz

Research output: Contribution to journalComment/debatepeer-review

Abstract

In the article, we mistakenly stated that we drew select items from the World Health Organization's Composite International Diagnostic Interview 2.0 (WHO CIDI-2.0) substance abuse module to assess substance use disorders. However, we actually used select items from the WHO World Mental Health-CIDI [WMH-CIDI]: http://www.hcp.med.harvard.edu/wmhcidi/index.php). Additionally, the DSM-5 has only one set of criteria for all substance use disorders, including tobacco. Because the WMH-CIDI does not contain all the criteria for DSM-5 Tobacco Use Disorder, we adapted the language from the WMH-CIDI items from the drug section to assess tobacco use disorder. Readers of our article should note the mislabeling “modified CIDI-2” in Fig. 1 and on page 95. The correct description should read “modified WMH-CIDI.” The authors would like to apologise for any inconvenience caused.

Original languageEnglish (US)
Pages (from-to)98
Number of pages1
JournalContemporary Clinical Trials
Volume51
DOIs
StatePublished - Nov 1 2016
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Erratum: Corrigendum to “Design of the NIDA clinical trials network validation study of tobacco, alcohol, prescription medications, and substance use/misuse (TAPS) tool” (Contemporary Clinical Trials (2016) 50 (90–97)(S1551714416301331)(10.1016/j.cct.2016.07.013))'. Together they form a unique fingerprint.

Cite this